MTEM vs. FBIO, BOLT, AEZS, MBRX, GRTX, GHSI, MNPR, ERNA, ATHE, and ELAB
Should you be buying Molecular Templates stock or one of its competitors? The main competitors of Molecular Templates include Fortress Biotech (FBIO), Bolt Biotherapeutics (BOLT), Aeterna Zentaris (AEZS), Moleculin Biotech (MBRX), Galera Therapeutics (GRTX), Guardion Health Sciences (GHSI), Monopar Therapeutics (MNPR), Eterna Therapeutics (ERNA), Alterity Therapeutics (ATHE), and Elevai Labs (ELAB). These companies are all part of the "pharmaceutical preparations" industry.
Molecular Templates (NASDAQ:MTEM) and Fortress Biotech (NASDAQ:FBIO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, community ranking, profitability, valuation, analyst recommendations, media sentiment and dividends.
Molecular Templates received 19 more outperform votes than Fortress Biotech when rated by MarketBeat users. Likewise, 67.32% of users gave Molecular Templates an outperform vote while only 64.86% of users gave Fortress Biotech an outperform vote.
Fortress Biotech has a consensus target price of $30.00, indicating a potential upside of 1,696.41%. Given Fortress Biotech's higher probable upside, analysts clearly believe Fortress Biotech is more favorable than Molecular Templates.
Molecular Templates has a net margin of -14.18% compared to Fortress Biotech's net margin of -74.12%. Fortress Biotech's return on equity of -770.86% beat Molecular Templates' return on equity.
95.5% of Molecular Templates shares are owned by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are owned by institutional investors. 18.7% of Molecular Templates shares are owned by insiders. Comparatively, 33.4% of Fortress Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Molecular Templates has higher earnings, but lower revenue than Fortress Biotech. Molecular Templates is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.
Molecular Templates has a beta of 1.15, meaning that its stock price is 15% more volatile than the S&P 500. Comparatively, Fortress Biotech has a beta of 1.56, meaning that its stock price is 56% more volatile than the S&P 500.
In the previous week, Fortress Biotech had 1 more articles in the media than Molecular Templates. MarketBeat recorded 3 mentions for Fortress Biotech and 2 mentions for Molecular Templates. Molecular Templates' average media sentiment score of 1.44 beat Fortress Biotech's score of 0.63 indicating that Molecular Templates is being referred to more favorably in the media.
Summary
Fortress Biotech beats Molecular Templates on 10 of the 17 factors compared between the two stocks.
Get Molecular Templates News Delivered to You Automatically
Sign up to receive the latest news and ratings for MTEM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MTEM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Molecular Templates Competitors List
Related Companies and Tools
